Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMetic to Report its Third Quarter 2013 Highlights and Financial Results and Hold Conference Call/Webcast

Marketwire

LAVAL, QUEBEC--(Marketwired - Nov. 11, 2013) - ProMetic Life Sciences Inc. (TSX:PLI)(OTCQX:PFSCF) ("ProMetic" or the "Corporation") today announced that it will report its financial results for the third quarter ended September 30, 2013 on Thursday November 14, 2013 before market trading hours.

ProMetic will host a conference call at 2:00pm (ET) on Thursday, November 14, 2013. The telephone numbers to access the conference call are (416) 981-9035 (International) and 1-800-759-0876 (North America Toll-Free). A live audio webcast of the conference call will be available via http://www.gowebcasting.com/5104

An audio replay of the call will be available as of Thursday November 14, 2013, at 3:00pm (E T). The numbers to access the audio replay are (416) 626-4100 (international) and 1 (800) 558-5253 (North America Toll Free) using access code: 21686603. 

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. (www.prometic.com) is a long established biopharmaceutical company with globally recognized expertise in bioseparations, plasma-derived therapeutics and small-molecule drug development. ProMetic offers its state of the art technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity technology that provides for highly efficient extraction and purification of therapeutic proteins from human plasma in order tto develop best-in-class therapeutics. ProMetic is also active in developing its own novel small-molecule therapeutic products targeting unmet medical needs in the field of fibrosis, anemia, neutropenia, cancer and autoimmune diseases/inflammation as well as certain nephropathies Headquartered in Laval (Canada), ProMetic has R&D facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK and business development activities in the U.S., Europe and Asia.

Pierre Laurin
President and CEO
ProMetic Life Sciences Inc.
p.laurin@prometic.com
450.781.0115

Frederic Dumais
Director, Communications & Investor Relations
ProMetic Life Sciences Inc.
f.dumais@prometic.com
450-781-0115